Walvax Biotechnology Co., Ltd. (SHE:300142)
China
· Delayed Price · Currency is CNY 10.09
-0.06 (-0.59%)
Apr 25, 2025, 2:45 PM CST
Walvax Biotechnology Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 142.16 | 419.39 | 728.65 | 427.75 | 1,003 | Upgrade
|
| Depreciation & Amortization | 388.54 | 317.23 | 264.93 | 143.84 | 123.95 | Upgrade
|
| Other Amortization | 23.02 | 16.1 | 10.57 | 5.71 | 4.46 | Upgrade
|
| Loss (Gain) From Sale of Assets | 1.77 | 0.83 | 0.38 | -0.23 | 1.08 | Upgrade
|
| Asset Writedown & Restructuring Costs | 7.68 | 11.31 | 1.66 | 5.11 | 2.41 | Upgrade
|
| Loss (Gain) From Sale of Investments | 93.31 | 227.64 | 187.54 | 222.86 | -285.29 | Upgrade
|
| Provision & Write-off of Bad Debts | 64.14 | 39.72 | -1.28 | -4.95 | -7.29 | Upgrade
|
| Other Operating Activities | 110.72 | 295.46 | 324.44 | 154.22 | 180.33 | Upgrade
|
| Change in Accounts Receivable | 781.3 | 535.7 | -1,241 | -614.65 | -1,495 | Upgrade
|
| Change in Inventory | 115.88 | -134.9 | -178.79 | -390.03 | -170.51 | Upgrade
|
| Change in Accounts Payable | -686.19 | -593.87 | 1,075 | 762.2 | 755.66 | Upgrade
|
| Operating Cash Flow | 1,037 | 1,134 | 1,201 | 705.28 | 114.19 | Upgrade
|
| Operating Cash Flow Growth | -8.58% | -5.64% | 70.36% | 517.62% | 84.13% | Upgrade
|
| Capital Expenditures | -550.03 | -945.52 | -1,091 | -1,103 | -407.13 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.47 | 0.74 | 0.34 | 3.73 | 4.47 | Upgrade
|
| Divestitures | - | 140 | 149.39 | 75.68 | 75 | Upgrade
|
| Investment in Securities | -722 | -10 | - | 41.18 | -407.56 | Upgrade
|
| Other Investing Activities | 4.9 | 6.78 | 6.26 | 5.74 | 5.22 | Upgrade
|
| Investing Cash Flow | -1,267 | -807.99 | -935.19 | -977.15 | -730 | Upgrade
|
| Short-Term Debt Issued | - | 4.5 | - | - | 40 | Upgrade
|
| Long-Term Debt Issued | 38.22 | 499.31 | 393.82 | 410 | - | Upgrade
|
| Total Debt Issued | 38.22 | 503.81 | 393.82 | 410 | 40 | Upgrade
|
| Short-Term Debt Repaid | -4.6 | -189.19 | - | - | - | Upgrade
|
| Long-Term Debt Repaid | -353.68 | -78.61 | -405.35 | -149.73 | - | Upgrade
|
| Total Debt Repaid | -358.28 | -267.8 | -405.35 | -149.73 | - | Upgrade
|
| Net Debt Issued (Repaid) | -320.07 | 236.01 | -11.54 | 260.27 | 40 | Upgrade
|
| Issuance of Common Stock | 0.18 | 36.18 | 397.11 | 1,221 | 150.21 | Upgrade
|
| Repurchase of Common Stock | - | -72.21 | -286.42 | - | - | Upgrade
|
| Common Dividends Paid | -40.94 | -19.98 | -50.11 | -83.31 | -31.73 | Upgrade
|
| Other Financing Activities | -10.21 | 56.64 | 45.77 | 338.48 | 56.6 | Upgrade
|
| Financing Cash Flow | -371.03 | 236.64 | 94.82 | 1,736 | 215.08 | Upgrade
|
| Foreign Exchange Rate Adjustments | 5.41 | 2.27 | 4.07 | -0.12 | -1 | Upgrade
|
| Net Cash Flow | -595.76 | 564.69 | 365.19 | 1,464 | -401.73 | Upgrade
|
| Free Cash Flow | 486.49 | 188.25 | 110.31 | -398.21 | -292.94 | Upgrade
|
| Free Cash Flow Growth | 158.43% | 70.65% | - | - | - | Upgrade
|
| Free Cash Flow Margin | 17.24% | 4.58% | 2.17% | -11.50% | -9.97% | Upgrade
|
| Free Cash Flow Per Share | 0.30 | 0.12 | 0.07 | -0.25 | -0.19 | Upgrade
|
| Cash Income Tax Paid | 136.82 | 264.12 | 309.57 | 244.55 | 212.66 | Upgrade
|
| Levered Free Cash Flow | 406.85 | 74.57 | -495.85 | -257.05 | -1,023 | Upgrade
|
| Unlevered Free Cash Flow | 412.12 | 78.29 | -491.4 | -253.44 | -1,022 | Upgrade
|
| Change in Net Working Capital | -535.58 | -171.07 | 370.62 | -120.6 | 1,463 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.